{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+in+the+Head+and+Neck&page=6", "query": { "condition": "Malignant Neoplasm in the Head and Neck", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 228, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+in+the+Head+and+Neck&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+in+the+Head+and+Neck&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T10:10:28.144Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02575404", "title": "GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "GR-MD-02", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-05-16", "completion_date": "2022-10-10", "has_results": false, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02575404" }, { "nct_id": "NCT06150664", "title": "A Phase 1 of CTX-8371 in Patients With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Triple Negative Breast Cancer", "Hodgkin Lymphoma", "Head and Neck Squamous Cell Carcinoma", "Malignant Melanoma" ], "interventions": [ { "name": "CTX-8371", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Compass Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2024-03-19", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 10, "location_summary": "Margate, Florida • Orlando, Florida • Sarasota, Florida + 6 more", "locations": [ { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06150664" }, { "nct_id": "NCT01852292", "title": "Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Buparlisib", "type": "DRUG" }, { "name": "Buparlisib matching Placebo", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2013-10-01", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2018-07-24", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 7, "location_summary": "Fayetteville, Arkansas • Boston, Massachusetts • St Louis, Missouri + 4 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01852292" }, { "nct_id": "NCT04628780", "title": "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Urothelial Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07209960", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-12-16", "completion_date": "2023-05-26", "has_results": true, "last_update_posted_date": "2024-07-29", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 13, "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04628780" }, { "nct_id": "NCT04354246", "title": "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Ovarian Cancer", "Lung Cancer", "Colon Cancer", "Plasma Cell Neoplasm", "Multiple Myeloma", "HNSCC", "Microsatellite Stable Colorectal Carcinoma", "MSS-CRC" ], "interventions": [ { "name": "Dose escalation: COM902 monotherapy.", "type": "DRUG" }, { "name": "Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)", "type": "COMBINATION_PRODUCT" }, { "name": "Cohort expansion: COM902 (RDFE) monotherapy.", "type": "DRUG" }, { "name": "Cohort expansion: COM902 in combination with COM701 (both at the RDFE).", "type": "DRUG" }, { "name": "Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Compugen Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2020-03-31", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 9, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Grand Rapids, Michigan + 6 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04354246" }, { "nct_id": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive", "Adenocarcinoma", "Bile Duct Cancer", "Biliary Tract Cancer", "Bladder Cancer", "Breast Cancer", "Breast Neoplasm", "Carcinoma, Ductal", "Carcinoma, Hepatocellular", "Cancer", "Lung Cancer, Non-Small-Cell", "Carcinoma, Ovarian Epithelial", "Carcinoma, Small Cell", "Carcinoma, Squamous", "Carcinoma, Transitional Cell", "Colorectal Cancer", "Esophagogastric Junction Neoplasms", "Inflammatory Breast Cancer", "Stomach Neoplasms", "Malignant Neoplasms", "Ovarian Neoplasms", "Pancreatic Cancer", "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER-2 Protein Overexpression", "HER-2 Gene Amplification", "Prostate Cancer", "Head and Neck Cancer", "Endometrial Cancer", "Lung Cancer, Small Cell" ], "interventions": [ { "name": "CT-0508", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carisma Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-02-02", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 7, "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660929" }, { "nct_id": "NCT04697446", "title": "External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "RET-fusion Non Small Cell Lung Cancer", "Lung Neoplasm", "Carcinoma, Non-Small-Cell Lung", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Neoplasms by Site", "Neoplasms", "Lung Diseases", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Diseases", "Head and Neck Neoplasms", "Carcinoma", "Neoplasms by Histologic Type", "Neoplasms, Germ Cell and Embryonal", "Neoplasms, Nerve Tissue", "Metastatic Non Small Cell Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 279, "start_date": "2020-12-01", "completion_date": "2021-10-31", "has_results": false, "last_update_posted_date": "2021-08-10", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697446" }, { "nct_id": "NCT03049280", "title": "Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Oropharyngeal Cancer" ], "interventions": [ { "name": "Transoral robotic surgery", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Intuitive Surgical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2017-04-17", "completion_date": "2017-12-26", "has_results": true, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 3, "location_summary": "Palo Alto, California • Celebration, Florida • Philadelphia, Pennsylvania", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Celebration", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049280" }, { "nct_id": "NCT05012098", "title": "Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Olfactory Neuroblastoma", "Esthesioneuroblastoma", "Neoplasm of the Nasal Cavity" ], "interventions": [ { "name": "Bintrafusp alfa/M7824", "type": "DRUG" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Tumor tissue biopsy", "type": "PROCEDURE" }, { "name": "Brain MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Dotate scan", "type": "DIAGNOSTIC_TEST" }, { "name": "PET FDG scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Nuclear bone scan", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2022-06-21", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05012098" }, { "nct_id": "NCT07038343", "title": "AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor Cancer", "Locally Advanced", "Metastatic Solid Tumors", "Lung Cancers", "Epithelial Tumor", "Biliary Tract Cancer (BTC)", "Urothelial Cancer", "Nasopharyngeal Cancers" ], "interventions": [ { "name": "AVZO-1418", "type": "DRUG" }, { "name": "Combination Agent 1", "type": "DRUG" }, { "name": "Combination Agent 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 480, "start_date": "2025-06-04", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-14T10:10:28.144Z", "location_count": 19, "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT07038343" } ] }